C. Battin

发表

Neuropilin-1 Acts as a Receptor for Complement Split Products

J. Leitner, G. Zlabinger, P. Steinberger, 2019, Front. Immunol..

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling

J. Leitner, G. Zlabinger, P. Steinberger, 2019, Scientific Reports.

Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.

Adam K. Sieradzan, P. Steinberger, K. Węgrzyn, 2022, Bioorganic chemistry.

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM

D. Olive, J. Leitner, P. Steinberger, 2022, Frontiers in Immunology.

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

J. Leitner, G. Zlabinger, P. Steinberger, 2017, Front. Immunol..

NKG2A‐checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA‐E

J. Leitner, P. Steinberger, F. Momburg, 2022, Immunology.

Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer

P. Steinberger, M. Kundi, C. Zielinski, 2022, Cancers.

TLR4/CD14/MD2 Revealed as the Limited Toll-like Receptor Complex for Chlamydia trachomatis-Induced NF-κB Signaling

H. Stockinger, P. Steinberger, A. Spittler, 2022, Microorganisms.

Generation of a Jurkat-based fluorescent reporter cell line to evaluate lipid antigen interaction with the human iNKT cell receptor

K. Hoffmann‐Sommergruber, P. Steinberger, W. Paster, 2019, Scientific Reports.

A human monocytic NF-κB fluorescent reporter cell line for detection of microbial contaminants in biological samples

R. Kunert, G. Zlabinger, P. Steinberger, 2017, PloS one.

4‐1BB costimulation promotes bystander activation of human CD8 T cells

J. Leitner, P. Steinberger, B. Bohle, 2020, European journal of immunology.

Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation - Design, Synthesis, and Cellular Studies

Adam K. Sieradzan, Agnieszka S. Karczynska, P. Steinberger, 2020, International journal of molecular sciences.

A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors

M. Preusser, L. Kenner, P. Steinberger, 2020, Frontiers in Immunology.

Saturated very long-chain fatty acids regulate macrophage plasticity and invasiveness

P. Steinberger, S. Kemp, P. Waidhofer-Söllner, 2022, Journal of neuroinflammation.

Targeting the HVEM protein using a fragment of glycoprotein D to inhibit formation of the BTLA/HVEM complex.

Adam K. Sieradzan, P. Steinberger, K. Węgrzyn, 2022, Bioorganic chemistry.

A Highly Sensitive Cell-Based TLR Reporter Platform for the Specific Detection of Bacterial TLR Ligands

K. Hoffmann‐Sommergruber, J. Leitner, P. Steinberger, 2022, Frontiers in Immunology.

The soluble cytoplasmic tail of CD45 regulates T‐cell activation via TLR4 signaling

P. Steinberger, J. Stöckl, Madhura Modak, 2021, European journal of immunology.

PD‐1 blocking antibodies moonlighting as killers

J. Leitner, P. Steinberger, K. Grabmeier-Pfistershammer, 2021, European journal of immunology.

BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation - design, synthesis and biological evaluation.

Adam K. Sieradzan, Agnieszka S. Karczynska, P. Steinberger, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents

J. Leitner, P. Steinberger, P. Waidhofer-Söllner, 2023, Cancer Immunology, Immunotherapy.

Interrogating ligand-receptor interactions using highly sensitive cellular biosensors

K. Stiasny, J. Leitner, P. Steinberger, 2023, Nature communications.

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer

K. Magiera-Mularz, K. Węgrzyn, E. Sikorska, 2024, Translational oncology.